Overview

Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer

Status:
Recruiting
Trial end date:
2024-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the effectiveness and safety of camrelizumab combined with radiotherapy and chemotherapy for recurrent or metastatic cervical cancer
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Treatments:
Cisplatin
Paclitaxel